All In Biotech

Drug Trial Radar · NCT06974929

A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer

An Open-Label, Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HRS-6209 Combination Therapy in Patients With Breast Cancer

Last checked: Nov 20, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

May 22, 2025

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Sponsor type
Industry
First posted
May 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HRS-6209 combined with other treatment regimens in breast cancer patients, and preliminarily observe its anti-tumor efficacy.

Conditions

  • Breast Cancer

Interventions

  • HRS-6209 CapsulesDrug

    Oral HRS-6209 capsules.

  • Letrozole TabletsDrug

    Oral Letrozole tablets.

  • HRS-2189 TabletsDrug

    HRS-2189 tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicity (DLT)Time frame: 28 days after the first dose.
  2. Maximum tolerated dose (MTD)Time frame: 28 days after the first dose.
  3. Recommended phase II dose (RP2D)Time frame: 28 days after the first dose.
  4. Adverse events (AEs)Time frame: About 1 year.
  5. Serious adverse events (SAEs)Time frame: About 1 year.
  6. Objective response rate (ORR)Time frame: About 1 year.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.